New trick for old drug; Vascepa cost effective for CV reduction
Top stories from the American Heart Association scientific sessions
7minVascepa gains event-reduction nod; diabetes ups ischemic risks.
8minPost-STEMI events less likely in women; bariatric surgery may lower stroke risk
7minNew trick for old drug; Vascepa cost effective for CV reduction
7minCard Talk: TAVR and glass ceilings
43minISCHEMIA trial, DAPA-HF, and valsartan recall: AHA Special
32minLong-awaited ISCHEMIA results to change practice, DAPA-HF elevates dapagliflozin for HFrEF
8minPot heightens stroke, arrhythmia risks; keeping low LDL and BP slashes lifetime heart risk
8min